MedPath

Nitrous Oxide and Risk of Cancer Recurrence After Colorectal Surgery: A Randomized, Blinded Study

Phase 3
Completed
Conditions
Colorectal Cancer
Interventions
Registration Number
NCT00781352
Lead Sponsor
The Cleveland Clinic
Brief Summary

This study was developed to test the hypothesis that the risk of colorectal cancer recurrence was similar in patients who were randomly assigned to 65% nitrous oxide or nitrogen during colorectal surgery.

Detailed Description

We conducted a 4- to 8-year follow-up of 204 patients with colorectal cancer who were randomly assigned to 65% nitrous oxide (n=97) or nitrogen (n=107), balanced with isoflurane and remifentanil. The primary outcome was the time to cancer recurrence. Our primary analysis was a multivariable Cox-proportional-hazards regression model that included relevant baseline variables. In addition to treatment group, the model considered patient age, tumor grade, dissemination, adjacent organ invasion, vessel invasion, and the number of nodes involved. The study had 80% power to detect a 56% or greater reduction in recurrence rates (i.e., hazard ratio of 0.44 or less) at the 0.05 significance level.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
408
Inclusion Criteria
  • Subjects age 18-18
  • ASA status 1-3
  • Informed consent
Exclusion Criteria
  • Acute bowel obstruction
  • Minor colon surgery

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
group 2nitrogenColorectal surgery with nitrogen administration
group 1nitrous oxideColorectal surgery with 65% nitrous oxide administration
Primary Outcome Measures
NameTimeMethod
To determine if the risk of colorectal cancer recurrence was similar in patients who were randomly assigned to 65% nitrous oxide or nitrogen during colorectal surgery.270 days post surgery
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Medical University of Vienna

🇦🇹

Vienna, Austria

© Copyright 2025. All Rights Reserved by MedPath